Noah C A Cooke1, Asem Bala2, Johane P Allard3, Susy Hota4, Susan Poutanen5, Valerie H Taylor6,7. 1. Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 2. Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 3. Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada. 4. Infection Prevention and Control Department, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 5. Departments of Microbiology and Medicine, University Health Network and Sinai Health, University of Toronto, Toronto, Canada. 6. Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. valerie.taylor@ucalgary.ca. 7. Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. valerie.taylor@ucalgary.ca.
Abstract
BACKGROUND: Bipolar disorder (BD) is a chronic, debilitating illness with significant medical morbidity, often secondary to current treatments, and a high recurrence rate. This burden of disease reflects limitations in the tolerability and efficacy of current treatments. There is a compelling body of evidence linking the gut microbiota to mental illness, and while microbial manipulation via probiotic use has been studied as a therapeutic in BD, targeted trials of fecal microbiota transplantation (FMT) have not been conducted in this population. METHODS AND DESIGN: We describe a pilot randomized controlled trial of FMT in participants with BD depression to assess the feasibility, efficacy, safety, and tolerability of this intervention. Individuals between 18 and 65 years of age will be enrolled in the study if they meet diagnostic criteria for a major depressive episode of at least moderate severity in the context of a BD diagnosis and have not responded to treatment for BD. Participants will be randomized 1:1 to receive either screened and processed donor stool (allogenic FMT) or their own stool (autologous FMT) via colonoscopy and monitored for 24 weeks post intervention. Depressive and manic symptoms, treatment acceptability, and gastrointestinal and other side effects are assessed at baseline (prior to randomization) and weekly. Stool samples to assess microbiome composition are obtained at baseline and 3 and 6 months. DISCUSSION: Currently, FMT represents a novel therapeutic option for treating BD depression. This protocol allows for the assessment of the feasibility, efficacy, acceptability, and safety of an intervention aimed at changing the microbiome in those with BD. Results from this pilot study will guide the development of larger trials of FMT for BD depression and may give more insight into how the gut microbiome are altered in those with BD depression. TRIAL REGISTRATION: Clinical Trials Gov NCT03279224.
RCT Entities:
BACKGROUND:Bipolar disorder (BD) is a chronic, debilitating illness with significant medical morbidity, often secondary to current treatments, and a high recurrence rate. This burden of disease reflects limitations in the tolerability and efficacy of current treatments. There is a compelling body of evidence linking the gut microbiota to mental illness, and while microbial manipulation via probiotic use has been studied as a therapeutic in BD, targeted trials of fecal microbiota transplantation (FMT) have not been conducted in this population. METHODS AND DESIGN: We describe a pilot randomized controlled trial of FMT in participants with BD depression to assess the feasibility, efficacy, safety, and tolerability of this intervention. Individuals between 18 and 65 years of age will be enrolled in the study if they meet diagnostic criteria for a major depressive episode of at least moderate severity in the context of a BD diagnosis and have not responded to treatment for BD. Participants will be randomized 1:1 to receive either screened and processed donor stool (allogenic FMT) or their own stool (autologous FMT) via colonoscopy and monitored for 24 weeks post intervention. Depressive and manic symptoms, treatment acceptability, and gastrointestinal and other side effects are assessed at baseline (prior to randomization) and weekly. Stool samples to assess microbiome composition are obtained at baseline and 3 and 6 months. DISCUSSION: Currently, FMT represents a novel therapeutic option for treating BD depression. This protocol allows for the assessment of the feasibility, efficacy, acceptability, and safety of an intervention aimed at changing the microbiome in those with BD. Results from this pilot study will guide the development of larger trials of FMT for BD depression and may give more insight into how the gut microbiome are altered in those with BD depression. TRIAL REGISTRATION: Clinical Trials Gov NCT03279224.
Authors: Simon J Evans; Christine M Bassis; Robert Hein; Shervin Assari; Stephanie A Flowers; Marisa B Kelly; Vince B Young; Vicky E Ellingrod; Melvin G McInnis Journal: J Psychiatr Res Date: 2016-12-10 Impact factor: 4.791
Authors: Kathleen R Merikangas; Hagop S Akiskal; Jules Angst; Paul E Greenberg; Robert M A Hirschfeld; Maria Petukhova; Ronald C Kessler Journal: Arch Gen Psychiatry Date: 2007-05
Authors: Annamaria Painold; Sabrina Mörkl; Karl Kashofer; Bettina Halwachs; Nina Dalkner; Susanne Bengesser; Armin Birner; Frederike Fellendorf; Martina Platzer; Robert Queissner; Gregor Schütze; Markus J Schwarz; Natalie Moll; Peter Holzer; Anna K Holl; Hans-Peter Kapfhammer; Gregor Gorkiewicz; Eva Z Reininghaus Journal: Bipolar Disord Date: 2018-07-26 Impact factor: 6.744